Introduction

Threatened miscarriage
Threatened miscarriage is a spontaneous miscarriage present with vaginal bleeding or any bloody vaginal discharge during the first half of pregnancy (Cunningham et al., 2005) . It is the most common complication in early pregnancy. About a quarter of recognized pregnancies have this symptom and half of those will end in miscarriage (Everett, 1997) . The causes of spontaneous miscarriage are diverse and comprise chromosomal, genetic, anatomical, immunological, hormonal, infectious and psychological factors (Bulletti et al., 1996) . In many cases, however, the specific underlying causes have not been identified (Orvieto et al., 1991) . The risk of miscarriage increases with parity as well as maternal and paternal age. After the age of 30 -35 years, fertility declines and the rate of spontaneous miscarriage increases with a significant social and economic impact (Brock and Holloway, 1990) .
The vaginal bleeding in threatened miscarriage is frequently slight and will subside spontaneously. Clinical care typically includes pelvic examination to exclude inevitable miscarriage, ultrasound to confirm viable intrauterine pregnancy and laboratory studies to monitor growth of the fetus. The vaginal bleeding may persist for days or weeks and progress no matter what is done. Expectant and medical management has not been shown to provide an additional benefit; bedrest, progesterone or chorionic gonadotrophin supplements do not significantly prevent pregnancy loss (Aleman et al., 2005; Hass and Ramsey, 2008; Devaseelan et al., 2010) .
Chinese medicines for threatened miscarriage
For more than 5000 years, Traditional Chinese Medicine has employed a range of unique clinical practices to maintain health (Giovanni, 1997) . The practices include acupuncture (inserting fine needles into specific points namely acupoints on the body), moxibustion (burning dried mugwort on the acupoints in conjunction with acupuncture), food therapy (individualizing dietary recommendations for a health condition), Chinese medicines (a collection of crude medicines, prepared drugs in slices, patent medicines and simple preparations), cupping (creating vacuum in several glass spheres on the body), Qigong (breathing and meditation exercise) and Tuina (body massage akin to acupressure). Most of these approaches have been disseminated to other countries since the sixth century BC (Unschuld, 1985) . Traditional Chinese Medicine is currently well accepted as a mainstream of medical care throughout East Asia and is considered a complementary or alternative medicine in the Western world (Basics, 2010) .
Chinese medicine is a common name for Chinese Materia Medica, which has therapeutic properties for medical treatment and healing (Read, 1976) . It is considered as a primary modality of internal medicine in Traditional Chinese Medicine (Holland, 2000) . Nowadays Chinese medicines and other herbal medicines are commonly used to promote maternal and fetal health and to relieve medical problems during pregnancy worldwide (Hemminki et al., 1991; Wang et al., 1995; Gharoro and Igbafe, 2000; Gibson et al., 2001; Hollyer et al., 2002; Mantani, 2003; Nordeng and Haven, 2004; Ong et al., 2005; Della et al., 2006; Chuang et al., 2009; Holst et al., 2009) . Chinese medicines are frequently used in threatened miscarriage (Li, 2011) in order to prevent pregnancy loss (Liu, 2002) .
Chinese medicines are regarded by the public and some health-care providers as gentle and safe (Marcus and Snodgrass, 2005) . Although there is no scientific basis for the safety claim, 30-50% of pregnant women use Chinese medicines to maintain good health and reduce the need for Western medication (Westfall, 2001; Ong et al., 2005) . Despite the potential beneficial effects of Chinese medicines in threatened miscarriage , no data are available to confirm the safety of Chinese medicines and no regulations have been established to monitor and control its clinical applications in pregnancy. In our animal studies of the commonly used Chinese medicines for threatened miscarriage, we worried about the identified reproductive toxicity, including fetal resorption, growth restriction and congenital malformations Wang et al., 2012) . We hypothesized that Chinese medicines may also be associated with adverse outcomes in human pregnancy. In this study, we have focused on threatened miscarriage and aimed to identify and describe the adverse events of Chinese medicines by systematic review and meta-analysis, which included adverse effects or toxicity of medicine, failure of intervention and adverse pregnancy and perinatal outcomes. This has not been done previously.
Materials and Methods
Study characteristics
This systematic review focused on clinical studies involving women with threatened miscarriage, the most common application of Chinese medicine during pregnancy (Li, 2011) . All published and unpublished studies that evaluated the adverse effects of Chinese medicines for threatened miscarriage were considered for review. Clinical studies included both uncontrolled studies and controlled studies, which compared Chinese medicines or combined medicines to a comparison group receiving no therapy (placebo), minimal therapy (hospitalization or bedrest only) or another therapy/treatment, were considered. Outcome measures included adverse events in mothers and fetuses.
Study design
Studies included both experimental and observational studies: (i) randomized control trials (RCTs), (ii) quasi-RCTs if the randomization methods were not adequate, (iii) controlled trials if no randomization was carried out; (iv) cohort studies if the study methods were not specified or assessed by RCTs and (v) case series and case reports. Observational studies were considered in this review because many adverse events are very uncommon and also take a long period to be observed. An intervention period of at least 1 week with either short-term or long-term follow-up and Chinese medicines, or in conjunction with any other intervention, as an independent factor on outcomes of health, were included for this study. The intervention duration of at least 1 week was based on capturing as many potentially effective interventional studies as possible. The primary outcome was adverse effects or toxicity of the Chinese medicines. Adverse effects and toxicity of Chinese medicines were defined as harmful and undesired side effects and toxic effects resulting from the treatment. Secondary outcomes were failure of the interventions, and adverse pregnancy and perinatal outcomes. Failure of intervention for threatened miscarriage was defined as inevitable miscarriage presented with vaginal bleeding and pregnancy loss. Adverse pregnancy outcomes were defined as pregnancy complications, and maternal morbidity and mortality, such as preterm labor, post-date delivery, gestational diabetics and hypertension and maternal death. Adverse perinatal outcomes were defined as prenatal and post-natal morbidity and mortality, including intrauterine infection, asphyxia, neurodevelopmental consequence, congenital malformation and neonatal death. Studies were excluded if (i) no ultrasound examination was provided to confirm the viable pregnancy, (ii) complicated or recurrent miscarriage were included for intervention, (iii) various herbal agents and products were included, e.g. green tea and ginger, which are widely used as daily pharmanutrients for general health and (iv) the study was not published in either English or Chinese.
Search strategy
A systematic review of the literature was conducted in December 2011 across the following databases: MEDLINE, PubMed, Cochrane Library, International Clinical Trials Registry Platform (ICTRP), EMB Reviews (including Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, Cochrane Methodology Register, ACP journal club), EMBASE, CINAHL, NHS Evidence, Wiley InterScience, Chinese Clinical Trial Registry, China Journal Net and WanFang database, with no time limit applied to any database. The reference lists of review articles and eligible studies were hand searched to identify other potentially eligible studies. Abstracts from conference proceedings were also considered to identify further studies that were not yet published. The search terms, adapted when required for each database, to identify Chinese medicines interventions in threatened miscarriage are presented in Supplementary data, Table SI.
Data extraction
Two co-authors (L.L. and L.X.D.) independently extracted data from a subset of the articles into data summary tables. Data regarding the study design, population(s) studied, assessment of interventions, measure of adverse events (short-term and long-term adverse outcomes), timing of measurement(s) and prevalence of outcomes were extracted from each included study. Quality analysis was performed based on the Cochrane Handbook of Systematic Reviews and Quality of Reporting of Meta-Analysis checklist. A formal assessment of study quality was performed for each study using a standardized quality assessment form adopted from Newcastle-Ottawa Quality Assessment Scale (Stang, 2010) . The intent was to perform a quantitative synthesis of the data where possible, dependent on the quality and diversity of the data. Meta-analysis was performed for RCTs and quasi-RCTs, otherwise controlled trials were included when there were not enough RCTs or quasi-RCTs. Sensitivity analysis was carried out to explore the effect of trial quality on overall result. Particularly, fixed-effect meta-analyses would be used for combining data in the absence of heterogeneity. In the presence of heterogeneity (I 2 . 50%), where results were being pooled from studies examining different interventions, or where it was not clear that the same outcome was being measured in all studies, random-effects meta-analyses would be used. Descriptive methods were applied to report and summarize the adverse outcomes of Chinese medicines for case reports and case series.
Results
Identification of articles Figure 1 shows the study selection according to PRISMA guidelines (Moher et al., 2009) . In total, 591 publications on Chinese medicines for threatened miscarriage were identified from the database search, but none were obtained from other sources. After screening the titles and abstracts, 65 commentary and 67 review articles were excluded. One hundred and eight-seven duplicated publications were also excluded. Full texts of remained 272 clinical studies were assessed for study eligibility. Adverse effects of Chinese medicines were not reported as an outcome measure in 232 studies. Adverse effects were not due to the intervention (outcomes before intervention) in one study , pregnancies of gestational age over 30 weeks were recruited in four studies (Wang et al., 2008; Jiang, 2009; Meng, 2009; Bi, 2010) , recurrent miscarriage was included in one study (Pan, 2008) , different pharmaceuticals were compared in one study (Lu et al., 2007) and Chinese medicines were included in the control group in one study (Zhang, 2009) . These 240 studies were also excluded, leaving 32 clinical studies with full records on the adverse effects of Chinese medicines for threatened miscarriage. These were selected for quantitative or qualitative synthesis for the review. (Li et al., 2006; Zhang et al., 2000) , while the other 7 RCTs did not report details of the randomization methods (Yang, 1992; Zhang et al., 2005; He and Che, 2007; Teng and Wu, 2008; Zhao et al., 2008 Zhao et al., , 2010 Yue et al., 2009) . The randomization method of the quasi-RCT was inadequate by the visiting date of the participants only (Song and Zhu, 2007) . Two studies both did not mention if any randomization method was used and were classified as nonrandomized controlled studies (Gong and Chen, 1993; Zhou, 2006) . The RCTs, quasi-RCT and non-randomized controlled studies consisted of two or three intervention groups, Chinese medicines alone, Continued pharmaceuticals alone and combined Chinese medicines and pharmaceuticals. All pharmaceuticals were Western medicines, including progesterone and oestrogen derivatives, HCG and vitamins C and E. Most case series only had a single Chinese medicines group, except one case series included combined Chinese medicines and pharmaceuticals as treatment group (Wang and Wang, 1987 
Study designs and methods
Continued
Chinese medicines for threatened miscarriage 2009). In addition, the dosage of the Chinese medicines varied from the smallest 2 g in one pack per day (Song and Zhu, 2007) to the largest 30 g in one pack per day (Li et al., 2006) . The course of the regimes ranged from 7 days (Wu and Ji, 1994; Song and Zhu, 2007) up to term delivery (Wu and Ji, 1994; Chou, 2002) , but seven studies did not report the duration of interventions (Wu, 1987; Tian and Li, 1991; Yang, 1992; Zhu and Li, 1992; Chen, 1997; Zhou, 1997; Chen and Yun, 1999) . For the pharmaceuticals used in RCTs, quasi-RCT and controlled trials, progesterone was commonly used together with Vitamin E for a week (Zhang et al., 2000; Li et al., 2006; Song and Zhu, 2007; Teng and Wu, 2008; Zhao et al., 2008 Zhao et al., , 2010 Yue et al., 2009) or HCG for 1-2 weeks (Zhang et al., 2005; Zhou, 2006) . All studies reported 100% compliance to complete the interventions, except Teng & Wu's study (Teng and Wu, 2008) (Table II) .
Baseline, exclusion and follow-up
The number of participants in most studies was ,100 (Table I and  Supplementary data, Table SIII) , only 5 studies included .200 subjects (Yang, 1992; Zhou, 1997; Chen et al., 2001; Zhang et al., 2000; He and Che, 2007) and 2 studies included .300 subjects (Zhou, 1997; Zhang et al., 2000) . The gestational age of participants in most studies was ,12 weeks of pregnancy, but eight studies included pregnancies from 12 to 20 weeks (Li, 1989; Tian and Li, 1991; Kang et al., 1998; Wang and Li, 2000; Luo et al., 2007; Gu et al., 2008; Xu, 2008; Yue et al., 2009) , two studies included up to gestational 30 weeks (Zhang et al., 2000; He and Che, 2007) and six studies did not report the details (Wu, 1987; Yang, 1992; Chen, 1997; Cui, 1998; Chou, 2002; Zhou, 2006) . Only 11 studies clearly excluded ectopic pregnancy, molar pregnancy, uterine abnormalities or other medical complications in the subject recruitment (Tian and Li, 1991; Chen, 1997; Cui, 1998; Kang et al., 1998; Chen et al., 2001; Zhang et al., 2005; Li et al., 2006; Song and Zhu, 2007; Teng and Wu, 2008; Zhao et al., 2008; Yue et al., 2009 ). In the other 21 studies, 11 did not report the exclusion criteria (Zhu and Li, 1992; Wu and Ji, 1994; Chen and Yun, 1999; He, 1997; Zhou, 1997 Zhou, , 2006 Wang and Li, 2000; Zhang et al., 2000; Xu, 2001; Chou, 2002; Luo et al., 2007) , while the other 10 studies did not provide any information (Wang and Wang, 1987; Wu, 1987; Li, 1989; Yang, 1992; Gong and Chen, 1993; He and Che, 2007; Gu et al., 2008; Xu, 2008; Ye and Qiu, 2008; Zhao et al., 2008) . Short-term and long-term outcome measures were both included in most studies, except two studies did not measure short-term outcomes (Yang, 1992; Zhao et al., 2008) , while six studies did not measure long-term outcomes (Gong and Chen, 1993; Wu and Ji, 1994; Chen et al., 2001; Zhang et al., 2005; Gu et al., 2008) . For short-term outcomes, most studies followed-up the subjects immediately or up to 2 weeks after interventions. For long-term outcomes, most studies followed-up Quality score: total score obtained from the quality assessment according to Newcastle -Ottawa Quality Assessment Scale (see Supplementary data, Table SIV ). Short-term follow-up include adverse effects and toxicity during intervention or intervention failure and outcomes; long-term follow-up include adverse pregnancy or perinatal outcomes.
b Parameters and durations of the long-term and short-term follow-up are available in Supplementary data, Table SV. the subjects around a month after intervention or until delivery, except for seven studies which prolonged the follow-up to years after delivery (Yang, 1992; Zhu and Li, 1992; He, 1997; Wang and Li, 2000; Zhang et al., 2000; Xu, 2001 Xu, , 2008 .
Adverse outcomes
In these 32 selected trials, the reported adverse outcomes included the adverse effects and toxicity of Chinese medicines, failure and complications of the intervention, adverse pregnancy outcomes and adverse perinatal outcomes. Owing to the substantial diversity of the selected studies with respect to quality, methodology, intervention variations, sample characteristics and outcome reporting, only a few studies meet the requirements for the planned quantitative data synthesis, comparing the adverse outcomes by meta-analysis. We also provided a qualitative data synthesis, presenting the major results of the studies in the text and summary tables.
Adverse effects and toxicity of Chinese medicines
In most studies, adverse effects and toxicity of the Chinese medicines as one of the short-term outcome measures were not studied (Table I) . Only 2 RCT studies with 130 participants (Zhang et al., 2005; Teng and Wu, 2008) reported adverse effects and toxicity of combined Chinese and Western medicines or Chinese medicines alone, but not Western medicines alone. No adverse effects were reported under combined medicines, but minor adverse effects were observed in 2-8% of women with Chinese medicine alone treatment. The effects included dry mouth, constipation and insomnia.
No adverse effects and toxicity were identified in the quasi-RCT in either intervention (Song and Zhu, 2007) . The controlled trials did not report adverse effects and toxicity after interventions (Gong and Chen, 1993; Zhou, 2006) . No meta-analysis was performed. Two case series reported no adverse effect and toxicity after Chinese medicines treatment (Wu and Ji, 1994; Gu et al., 2008) . Only one case series identified 0.9 -3.9% of some gastrointestinal effects, including nausea, dry mouth, anorexia and constipation (Chen et al., 2001 ).
Failure of the intervention and complications
Two RCTs (Zhang et al., 2000; Zhang et al., 2005) and 1 quasi-RCT (Song and Zhu, 2007) with 778 participants compared Chinese medicines alone with Western medicines alone. Failure of Chinese medicine treatment occurred in 3.1 -18.5%, while failure of Western medicine treatment occurred in 15-56.9%; however, none reported the details of the complications of threatened miscarriage after the failure. In these three studies, there was significant heterogeneity (x 2 ¼ 20.46, df ¼ 2, I 2 ¼ 90%, P , 0.0001), which indicated that the magnitude of the effects among the studies was not consistent, or the data might be at risk of allocation bias. Meta-analysis showed that Chinese medicine alone resulted in no significant difference in intervention failures compared with Western medicine alone [relative risk (RR) ¼ 0.24; 95% confidence interval (CI): 0.06 -1.00, I 2 ¼ 90%, random-effects model, evidence from three RCTs and quasi-RCTs, Fig. 2a ). Sensitivity analysis was carried out to explore the impact of the quality of original trials, and the results showed no difference whether the quasi-RCT study was included or not in the meta-analysis.
Five RCTs studies (Zhang et al., 2005; Li et al., 2006; He and Che, 2007; Teng and Wu, 2008; Yue et al., 2009 ) with 482 participants compared combined medicines with Western medicines. Failure of combined treatment occurred in 7-22.3%, while failure of Western medicine treatment occurred in 15 -31%; however, no details of the complications of threatened miscarriage were available. In these five studies, there was no significant heterogeneity (x 2 ¼ 2.86, df ¼ 4,
. Meta-analysis showed the incidence of intervention failure in combined medicines was significantly lower than that in Western medicines alone (RR ¼ 0.46; 95% CI: 0.30 -0.70, I 2 ¼ 0%, fixed-effect model, evidence from 5 RCTs and quasi-RCTs, Fig. 2a) . Two controlled trials (Gong and Chen, 1993; Zhou, 2006) with 115 participants compared combined medicines, Chinese medicines alone and Western medicines alone. The incidences of intervention failure were recorded as 0-10.4, 5-16.6 and 30 -33%, respectively. In these two studies, there were no significant heterogeneity in either comparison (x 2 ¼ 0.77 -1.20, df ¼ 1,
Meta-analysis showed that there was no significant difference between Chinese medicines alone and Western medicines alone interventions (RR ¼ 0.30; 95% CI: 0.09-0.99, I 2 ¼ 0%, fixed-effect model, evidence from two controlled trials, Fig. 2a ) or between combined medicines and Western medicines alone interventions (RR ¼ 0.21; 95% CI: 0.06-0.67, I 2 ¼ 17%, fixed-effect model, evidence from two controlled trials, Fig. 2a ). Twenty case series with 1532 participants studied Chinese medicines alone. Chinese medicines intervention failed to improve miscarriage symptoms and prevent miscarriage in 2-20% cases; however, their clinical outcomes after the intervention failure had not been followed at all.
Adverse pregnancy outcomes
Adverse pregnancy outcomes were only reported in five RCT studies (Li et al., 2006; He and Che, 2007; Zhao et al., 2008; Yue et al., 2009; Zhao et al., 2010) and one controlled trial (Zhou, 2006) . However, the incidents were not described separately in either intervention group in two RCT studies (Zhao et al., 2008 (Zhao et al., , 2010 and in the Western medicines group in another RCT study (Yue et al., 2009) . One RCT study (He and Che, 2007) and the controlled trial (Zhou, 2006) compared the adverse pregnancy outcomes in Chinese medicines alone and Western medicines alone; and the remaining one RCT study compared the adverse pregnancy outcomes of combined medicines and Western medicines alone (Li et al., 2006) . The adverse pregnancy outcomes included preterm labour (1.7 -5%), postdate delivery (1.7%) and diabetic pregnancy (3.7%). Results from one RCT comparing Chinese medicines alone versus Western medicines alone (He and Che, 2007) and one RCT comparing combined medicines versus Western medicines alone (Li et al., 2006) on the adverse pregnancy outcome were not conclusive. Since insufficient RCT studies were available for meta-analysis, controlled trials were also included for further analysis. Meta-analysis of a single RCT study (Li et al., 2006) and a single controlled trial (Zhou, 2006) on the adverse pregnancy outcome of Chinese medicines alone and Western medicines alone (RR ¼ 1.65, 95% CI: 0.22 -12.07, I
2 ¼ 0%, fixed-effect model, evidence from 1 RCT and 1 controlled trial, Fig. 2b ) or combined medicines and Western medicines alone (Fig. 2b) could not be conclusive.
Chinese medicines for threatened miscarriage Most case series did not report adverse pregnancy outcomes. Only seven cases series reported no adverse pregnancy outcome after Chinese medicine treatment (Wang and Wang, 1987; Li, 1989; Zhu and Li, 1992; Kang et al., 1998; Chen and Yun, 1999; Wang and Li, 2000; Chou, 2002) . Another four case series identified adverse pregnancy outcomes after Chinese medicine treatment (Tian and Li, 1991; Zhou, 1997; Cui, 1998; Luo et al., 2007) . Preterm deliveries were also identified in three case series (Zhou, 1997; Cui, 1998; Luo et al., 2007) in 0.7-6.4%. Other adverse maternal outcomes were identified in two case series, including premature rupture of membranes in 2.1% in one case series (Cui, 1998) and stillbirths in 2.9% in other case series (Tian and Li, 1991) .
Adverse perinatal outcomes
Adverse perinatal outcomes were reported in seven RCT studies (Yang, 1992; Zhang et al., 2000; Li et al., 2006; He and Che, 2007; Zhao et al., 2008 Zhao et al., , 2010 Yue et al., 2009) , one quasi-RCT study (Song and Zhu, 2007) and one controlled trial (Zhou, 2006) . However, the incidents were not described in the control group in three RCT studies (Zhang et al., 2000; Zhao et al., 2008; Yue et al., 2009) . In four RCT and one quasi-RCT studies (Li et al., 2006; He and Che, 2007; Song and Zhu, 2007; Zhao et al., 2008 Zhao et al., , 2010 , no adverse perinatal outcomes were identified in either intervention group. No meta-analysis was performed. Neurodevelopmental morbidity was confirmed in one RCT study (Yang, 1992) , the incidence was 1.8 and 7.4% with Chinese medicines alone and with Western medicines alone, respectively. Neonatal death due to prematurity was identified in the controlled study (Zhou, 2006) , the incident was 5% in the combined medicines group, but not in the Chinese medicines alone and Western medicines alone groups.
Most case series reported adverse perinatal outcomes after Chinese medicines treatment, except five case series (Wang and Wang, 1987; Li, 1989; Wu and Ji, 1994; Chen et al., 2001; Gu et al., 2008) . No adverse perinatal outcomes were reported in the 11 case series, but neonatal death due to prematurity, asphyxia or infection were identified in three case series with an incidence rate ranging from 0.7 to 6.4% (Wu, 1987; Zhou, 1997; Cui, 1998) , while an unspecified malformation was recorded in one case series with an incidence rate of 0.9% (Chou, 2002) and epilepsy and abnormal intellectual development in one case series with an incidence rate of 0.3% (Zhou, 1997) .
Discussion
Summary of evidence
In this review, adverse events of Chinese medicines for threatened miscarriage, including adverse effects or toxicity, failure of intervention, adverse pregnancy and perinatal outcomes, were studied. Data were pooled from studies that were clinically very heterogeneous; there were large differences across studies in study design, interventions and outcome measures. Furthermore, data were often statistically herterogeneous as reflected by an I 2 value .50%. As a consequence the results presented should be considered with care. Meta-analysis demonstrated that intervention failure was significantly lower in the combined Chinese medicines groups than in the Western medicines controls. No significant differences were found in adverse effects and toxicity, or in adverse pregnancy and perinatal outcomes. This review identified the adverse maternal and perinatal outcome of Chinese medicines for threatened miscarriage. Preterm premature rupture of membranes (PPROM) was recorded in a study with incidence of 2.1%. Prematurity and associated neonatal mortality were recorded in several studies with an incidence ranging from 0.7 to 6.4%. It is well known that threatened miscarriage is associated with the risk of suboptimal pregnancy outcome (van Oppenraaij et al., 2009; Saraswat et al., 2010) . Women with threatened miscarriage have a significantly higher incidence of antepartum haemorrhage (overall 1.2%). They are also more likely to experience PPROM (overall 1.9%), preterm delivery (overall 11.0%) and to have babies with an intrauterine growth restriction (overall 8.3%). First-trimester bleeding is also associated with significantly higher rates of perinatal mortality (overall 1.8%) and low and/or very low birthweight babies (overall 11.0%, odd ratios . 2.0). In comparison, after treatment of threatened miscarriage with Chinese medicines, no antepartum haemorrhage, intrauterine growth restriction or low birthweights were recorded and the prematurity rate was relatively lower, but the PPROM rate was slightly higher. The neonatal death rate due to prematurity with respect to first trimester bleeding is 2.6-8.5% (Williams et al., 1991) , which is comparable to our current review. These results suggest that Chinese medicines treatment for threatened miscarriage may not be associated with an increased risk of preterm delivery and neonatal mortality.
On the other hand, malformations were reported in 0.9% of babies whose mothers had taken Chinese medicines for threatened miscarriage. Unfortunately, the details of the malformations were not specified. Although at least half of threatened miscarriages are associated with chromosomal anomalies of the conceptus, the risk of birth defects does not appear to be increased significantly. The overall incidence rates of congenital anomalies in women with and without vaginal bleeding in first trimester are 3.2 and 2.7%, respectively (Saraswat et al., 2010) . The results suggest that Chinese medicines for threatened miscarriage may not be associated with increased risk of congenital malformation.
Limitations
Very few clinical studies of Chinese medicines for threatened miscarriage were eligible for this review. Over 90% of the identified studies did not include adverse effects as one of the study outcome measures. It may be because the incidence of adverse events was indeed too rare or because the awareness on the adverse effects was actually too low. In our qualitative analysis, a low rate of adverse events after maternal exposure to Chinese medicines for threatened miscarriage was recorded, but the incidences were not too low to be easily missed. Hence, lack of awareness on the safety issue of Chinese medicines in general could be the main reason of limited studies being available for systematic review.
Apart from limited records in adverse outcomes, study designs were also restricted. No RCTs were placebo controlled and one RCT had non-placebo controls (Yang, 1992) . Of the RCTs, only two were adequately randomized, while the other RCTs only mentioned with 'participants were randomly received different treatments'. The quasi-RCT used an inadequate randomization method by 'visiting date'. All 20 case series studies had no controls for comparison, allocation methods were not described and their quality scores were not high. Furthermore, the study results were questionable. Though all the studies had high compliance and drop-out rates were not high, sample sizes of the selected studies were still very small. Some important demographic data and study exclusion criteria were not provided. Different studies used different Chinese medicine formulae to treat threatened miscarriage and also there were large variations in the dose, dosing and duration of the intervention amongst the studies. Most studies followed-up the pregnancy until delivery, but the outcome parameters in the pregnancy and perinatal complications were rather inconsistent. Few studies monitored adverse effects and toxicity of Chinese medicines, and complication of miscarriage was unknown. Owing to the limited number of RCTs and the clinical heterogeneity between studies, additional metaanalysis to evaluate the adverse effects of Chinese medicine for threatened miscarriage was not available.
Difficulties
Unlike Western herbalism, Chinese medicines include many animal materials and even mineraloid remedies as well as medicinal herbs (National Phamacopoeia Committee, 2005) . In addition, Chinese medicines are formulated and individualized. A typical formula may contain 3-25 Chinese medicines. Most of the formula are processed by decoction in boiling water for hours and are orally administered as a 'soup' (Scheid, 2002) , though it can be supplied as powders, soluble granules and tablets nowadays. As each Chinese medicine has its own properties and potential interactions, the application of formulized and individualized medication enhance the therapeutic actions of some herbs and all the herbs collaborate in each other for the treatment. However, the adverse effects and toxicity of Chinese medicines may vary in different combinations, preparations and individuals. It is difficult to identify which Chinese medicine contributes to a specific adverse effect.
Conclusions and recommendations
This is the first systematic review to evaluate the clinical studies of Chinese medicines for threatened miscarriages in identifying their potential adverse effects on mothers and fetuses. Unfortunately, the evidence regarding the use of Chinese medicines for threatened miscarriage on adverse effects/toxicity, and adverse pregnancy and perinatal outcomes, is limited. Studies vary considerably in design, interventions and outcome measures; therefore, conclusive results remain elusive. Rigorous scientific and clinical studies are necessary to confirm the risk of Chinese medicines.
The active ingredients of the Chinese medicines are also chemicals that are similar to prescription pharmaceuticals. Chinese medicines are not free of risk; similar to Western pharmaceutical medicines, they have the potential to cause adverse effects. Thus, Chinese medicines in Traditional Chinese Medicine may not only result in maternal manifestations that indirectly affect fetal health, but they may also harm the fetus directly. Despite variations in clinical practice and therapeutic prescription, Chinese medication in Traditional Chinese Medicine should comply with the same modern pharmacological principles as Western Medicine. Chinese medicines may be beneficial, but may also adversely affect both mothers and fetuses in utero.
International regulations have not been designed or specified to categorize these Chinese medicines for use in pregnancy. Detailed reproductive toxicity and pharmacotoxicity studies that assess the potential risk of Chinese medicines during pregnancy are still not available, just as conventional medications have not been thoroughly tested in pregnancy. We hope that more comprehensive and systematic experiments will be conducted in the near future. Until more reliable and scientific research data become available, clinicians should appraise both the risks and benefits before recommending these medicines to pregnant women. Both Chinese and Western physicians should explicitly document the history of the use of any Chinese medications during pregnancy to prevent and recognize potential serious problems associated with their use. They should also encourage discontinuation of Chinese medications during pregnancy to avoid adverse events before sufficient safety evidence become available. We recommend more systematic investigations of the safety implications of the use of Chinese medicines in animals. More studies and clinical trials in humans with a larger sample size are also mandatory.
Supplementary data
